Clinical Watch: August 2019

September 24, 2019

In this issue of Clinical Watch, we discuss the expanded indication for drugs to treat relapsing forms of multiple sclerosis. We suggest criteria for the relaunched IBS-C drug Zelnorm™ and review a clinical trial of a potentially disease-modifying sickle cell disease treatment. Finally, we review claims data to identify patients at risk for a fall.

For more information about a specific topic, please contact Janelle Sheen or Karen Powell. Be sure to stay tuned for future monthly updates. For more information about our solutions, please visit conduent.com/pharmacy solutions. 

Previous Flipbook
Modernizing Outbound Communication Print and Digital Processes for Business Efficiency
Modernizing Outbound Communication Print and Digital Processes for Business Efficiency

Next Article
Hub Collaboration: Igniting Efficiency for Patient Assistance Programs
Hub Collaboration: Igniting Efficiency for Patient Assistance Programs

Yet the process of getting patients going on medications through a PAP is often slowed or inhibited by the ...